R Scott Greer

Bio

R. Scott Greer, as managing director of Numenor Ventures, LLC, is a private investor in and consultant to the life sciences industry with over 35 years experience. Mr. Greer has made direct investments in over 25 healthcare, technology, and consumer product companies. He was a founder of Abgenix, Inc., a publicly traded biotechnology company focused on developing and commercializing human antibody based therapeutics, serving as its Chief Executive Officer from its inception in 1996 through 2002 and as its Chairman of the Board from 2000 until 2006. In 2006, Abgenix was acquired by Amgen, Inc. (Nasdaq: AMGN) for approximately $2.2 billion. Mr. Greer was an investor in and Chairman of the Board of Sirna Therapeutics, a publicly traded biotechnology company that was sold to Merck for $1.1 billion in 2007. He was a director of and investor in Auspex Pharmaceuticals, a publicly traded specialty pharmaceuticals company, that was sold to Teva Pharmaceuticals for $3.5 billion in 2015. Most recently he was Chairman of Calimmune, Inc., a private gene therapy company, that was acquired by CSL, Ltd. in a deal valued up to $416 million. Prior to forming Abgenix, Mr. Greer spent five years at Cell Genesys, Inc., a publicly traded biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development through its early development and initial public offering, and later as Senior Vice President of Corporate Development. Mr. Greer also held various positions at Genetics Institute, Inc., (acquired by American Home Products, Inc.). Mr. Greer is currently a director of several public biopharmaceutical and medical device companies including: Nektar Therapeutics (Nasdaq: NKTR), Versartis, Inc (Nasdaq: VSAR), Inogen, Inc. (Nasdaq: INGN), and Sientra, Inc. (Nasdaq: SIEN). In the past he was a director of Illumina, Inc. (Nasdaq: ILMN), CV Therapeutics, Inc. (Nasdaq: CVTX), Affymax, Inc. (Nasdaq: AFFY), Auspex, Inc. (Nasdaq: ASPX), BAROnova, Inc., StemCells, Inc. (Nasdaq: STEM), Chimeros, Inc., and Anaptys BioScience, Inc. (Nasdaq: ANAB). He also served as Chairman of the Board of Inogen, Inc., Calimmune, Inc., and Ablexis, Inc. Mr. Greer has a B.A. in economics from Whitman College and an M.B.A. from Harvard University. Prior to attending business school, Mr. Greer was an auditor with Coopers & Lybrand (now Pricewaterhouse Coopers, LLC) and was a certified public accountant. In 2000, Mr. Greer was honored as the Ernst & Young Entrepreneur of the Year (Northern California Life Sciences). Mr. Greer served on the board of the Santa Barbara Maritime Museum from 2003-2006.